How a Supreme Court fight over fish oil could raise your prescription drug costs
A Supreme Court case involving Hikma and Amarin could impact the availability of generic drugs and their prices. The dispute centers on the practice of 'skinny labeling,' which allows generics to enter the market sooner for unpatented uses. A ruling in favor of Amarin may lead to longer monopolies for brand-name drugs, resulting in higher costs for patients.
- ▪The case involves Hikma, a generic drugmaker, and Amarin, the maker of Vascepa, a brand-name fish oil drug.
- ▪Skinny labeling allows generics to market their products for unpatented uses, potentially saving patients billions.
- ▪A ruling favoring Amarin could discourage generic companies from using skinny labeling, leading to longer waits for lower-cost medications.
NPR — News files mainly under news. We currently carry 518 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | NPR — News |
| Canonical URL | https://www.npr.org/2026/04/29/nx-s1-5803137/supreme-court-generic-drugs-hikma |
| Publication time | Wed, 29 Apr 2026 05:00:00 -0400 |
| Retrieval time | 2026-04-29T09:11:54.484Z |
| Last seen | 2026-04-29T09:11:54.484Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | y9jvlB8nkoLY |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Health How a Supreme Court fight over fish oil could raise your prescription drug costs April 29, 20265:00 AM ET From By Leslie Walker sinceLF/iStockphoto/Getty Images The United States pays undeniably high prices for brand-name drugs. But when it comes to generics — the cheaper copycat medicines that now fill nine out of every 10 prescriptions in America — the country gets a very good deal. Americans pay less, on average, for generic medications than people in any other peer nation. But the wait for those savings can be long, with some brand-name monopolies lasting decades before a generic can hit the market. That wait could get longer — depending on the outcome of a case the Supreme Court is hearing Wednesday.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at NPR — News.
Discussion
0 commentsMore from NPR — News
